Exelixis Inc (EXEL) concluded trading on Wednesday at a closing price of $32.80, with 4.91 million shares of worth about $161.2 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 21.80% during that period and on February 12, 2025 the price saw a loss of about -0.03%. Currently the company’s common shares owned by public are about 281.73M shares, out of which, 277.26M shares are available for trading.
Stock saw a price change of -2.24% in past 5 days and over the past one month there was a price change of -7.08%. Year-to-date (YTD), EXEL shares are showing a performance of -1.50% which increased to 62.22% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $20.01 but also hit the highest price of $37.59 during that period. The average intraday trading volume for Exelixis Inc shares is 2.21 million. The stock is currently trading -2.96% below its 20-day simple moving average (SMA20), while that difference is down -4.50% for SMA50 and it goes to 17.63% higher than SMA200.
Exelixis Inc (NASDAQ: EXEL) currently have 281.73M outstanding shares and institutions hold larger chunk of about 87.36% of that.
The stock has a current market capitalization of $9.37B and its 3Y-monthly beta is at 0.61. PE ratio of stock for trailing 12 months is 18.50, while it has posted earnings per share of $1.77 in the same period. Its PEG reads 0.93 and has Quick Ratio of 3.58 while making debt-to-equity ratio of 0.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EXEL, volatility over the week remained 3.59% while standing at 3.45% over the month.
Stock’s fiscal year EPS is expected to rise by 12.18% while it is estimated to increase by 18.49% in next year. EPS is likely to grow at an annualized rate of 19.87% for next 5-years, compared to annual growth of 11.55% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on January 27, 2025 offering an Overweight rating for the stock and assigned a target price range of between $30 and $40 to it. On December 20, 2024, BMO Capital Markets Downgrade their recommendations, while on December 17, 2024, BofA Securities Downgrade their ratings for the stock with a price target of $39. Stock get an Outperform rating from RBC Capital Mkts on October 16, 2024.
